Ordena

Cercar

01/03/2022 Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
Wu, YL, John, T, Grohe, C, Majem, M, Goldman, JW, Kim, SW, Kato, T, Laktionov, K, Vu, HV, Wang, ZJ, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Atasoy, A, Herbst, RS, Tsuboi, M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 2022; 17(3)DOI:10.1016/j.jtho.2021.10.014. PMID:34740861. IF:20.400(Q1/1D).
01/03/2022 The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies
Sanchez, JM, Carratala, JV, Serna, N, Unzueta, U, Nolan, V, Sanchez-Chardi, A, Volta-Duran, E, Lopez-Laguna, H, Ferrer-Miralles, N, Villaverde, A, Vazquez, E. The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies. Pharmaceutics. 2022; 14(3)DOI:10.3390/pharmaceutics14030602. PMID:35335976. IF:5.400(Q1/2D).
01/03/2022 Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
Hernandez-Boluda, JC, Pereira, A, Zinger, N, Gras, L, Martino, R, Paneesha, S, Finke, J, Chinea, A, Rambaldi, A, Robin, M, Saccardi, R, Natale, A, Snowden, JA, Tsirigotis, P, Vallejo, C, Wulf, G, Xicoy, B, Russo, D, Maertens, J, Daguindau, E, Lenhoff, S, Hayden, P, Czerw, T, McLornan, DP, Yakoub-Agha, I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. BONE MARROW TRANSPLANTATION. 2022; 57(3)DOI:10.1038/s41409-021-01553-x. PMID:35066569. IF:4.800(Q1/2D).
01/03/2022 Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery
Serna, N, Pallares, V, Unzueta, U, Garcia-Leon, A, Volta-Duran, E, Sanchez-Chardi, A, Parlade, E, Rueda, A, Casanova, I, Falgas, A, Alba-Castellon, L, Sierra, J, Villaverde, A, Vazquez, E, Mangues, R. Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. JOURNAL OF CONTROLLED RELEASE. 2022; 343DOI:10.1016/j.jconrel.2022.01.017. PMID:35051493. IF:10.800(Q1/1D).